1. Scrip
  2. >>New Products

Kiadis Poised To Launch Lead Product ATIR101 In 2019

 
• By Sten Stovall

Launch approval of Netherlands-based Kiadis Pharma's lead asset ATIR101 looks likely in Europe by early-2019 for safer, more effective bone marrow transplants. US approval will take longer.

Stem cells
ATIR101 is filed in Europe for haploidentical haematopoietic stem cell transplants in patients with blood cancers • Source: Shutterstock

The CEO of Kiadis Pharma Netherlands BV is readying plans to commercialize its lead cell therapy asset in Europe by the second half of 2019 and believes the resulting revenues should put the Dutch biotech in a strong position for a later expected launch of its ATIR101 product in the US.

ATIR101 is filed in Europe for haploidentical haematopoietic stem cell transplants (HSCT) in patients with blood cancers, as the stem cell transplant process is potentially curative, but very dangerous, especially...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

Pipeline Watch: 12 Approvals And 26 Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Boehringer’s CMO On How AI, Integrated Evidence Generation Underpin Its Ambitious Launch Plans

 
• By Alexandra Shimmings

The German company has big plans for the next five years or so. Scrip speaks to its chief medical officer Lykke Hinsch Gylvin about how it is using AI and other innovative approaches to make good on its ambitions.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.